| Adverse Event (AE) . | Acute AE . | Chronic AE . |
|---|---|---|
| . | N = 20 . | N = 20 . |
| Motor Neuropathy | ||
| Grade 1 | – | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Sensory Neuropathy | ||
| Grade 1 | 3 (15%) | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Radiation Necrosis | ||
| Grade 1 | – | 1 (5%) |
| Xerostomia | ||
| Grade 1 | 4 (20%) | – |
| Nausea | ||
| Grade 1 | 3 (15%) | 3 (15%) |
| Grade 2 | 3 (15%) | – |
| Hearing Loss | ||
| Grade 1 | 1 (5%) | – |
| Grade 2 | – | 1 (5%) |
| Radiation Dermatitis | ||
| Grade 1 | 10 (50%) | – |
| Grade 2 | 1 (5%) | – |
| Fatigue | ||
| Grade 1 | 10 (50%) | 9 (45%) |
| Grade 2 | 3 (15) | 1 (5%) |
| Grade 3 | 1 (5%) | – |
| Headache | ||
| Grade 1 | 4 (20%) | 3 (15%) |
| Grade 2 | 1 (5%) | 2 (10%) |
| Gait Disturbance | ||
| Grade 1 | 3 (15%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Cognitive Disturbance | ||
| Grade 1 | 2 (10%) | 2 (10%) |
| Grade 2 | 3 (15%) | 1 (5%) |
| Memory Impairment | ||
| Grade 1 | 5 (20%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Alopecia | ||
| Grade 1 | 10 (50%) | 4 (20%) |
| Grade 2 | 3 (15%) | 2 (10%) |
| Adverse Event (AE) . | Acute AE . | Chronic AE . |
|---|---|---|
| . | N = 20 . | N = 20 . |
| Motor Neuropathy | ||
| Grade 1 | – | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Sensory Neuropathy | ||
| Grade 1 | 3 (15%) | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Radiation Necrosis | ||
| Grade 1 | – | 1 (5%) |
| Xerostomia | ||
| Grade 1 | 4 (20%) | – |
| Nausea | ||
| Grade 1 | 3 (15%) | 3 (15%) |
| Grade 2 | 3 (15%) | – |
| Hearing Loss | ||
| Grade 1 | 1 (5%) | – |
| Grade 2 | – | 1 (5%) |
| Radiation Dermatitis | ||
| Grade 1 | 10 (50%) | – |
| Grade 2 | 1 (5%) | – |
| Fatigue | ||
| Grade 1 | 10 (50%) | 9 (45%) |
| Grade 2 | 3 (15) | 1 (5%) |
| Grade 3 | 1 (5%) | – |
| Headache | ||
| Grade 1 | 4 (20%) | 3 (15%) |
| Grade 2 | 1 (5%) | 2 (10%) |
| Gait Disturbance | ||
| Grade 1 | 3 (15%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Cognitive Disturbance | ||
| Grade 1 | 2 (10%) | 2 (10%) |
| Grade 2 | 3 (15%) | 1 (5%) |
| Memory Impairment | ||
| Grade 1 | 5 (20%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Alopecia | ||
| Grade 1 | 10 (50%) | 4 (20%) |
| Grade 2 | 3 (15%) | 2 (10%) |
1Statistics presented: n (%).
AEs are defined as events experienced within 90 days of the start of RT; otherwise considered chronic maximum toxicities are presented.
| Adverse Event (AE) . | Acute AE . | Chronic AE . |
|---|---|---|
| . | N = 20 . | N = 20 . |
| Motor Neuropathy | ||
| Grade 1 | – | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Sensory Neuropathy | ||
| Grade 1 | 3 (15%) | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Radiation Necrosis | ||
| Grade 1 | – | 1 (5%) |
| Xerostomia | ||
| Grade 1 | 4 (20%) | – |
| Nausea | ||
| Grade 1 | 3 (15%) | 3 (15%) |
| Grade 2 | 3 (15%) | – |
| Hearing Loss | ||
| Grade 1 | 1 (5%) | – |
| Grade 2 | – | 1 (5%) |
| Radiation Dermatitis | ||
| Grade 1 | 10 (50%) | – |
| Grade 2 | 1 (5%) | – |
| Fatigue | ||
| Grade 1 | 10 (50%) | 9 (45%) |
| Grade 2 | 3 (15) | 1 (5%) |
| Grade 3 | 1 (5%) | – |
| Headache | ||
| Grade 1 | 4 (20%) | 3 (15%) |
| Grade 2 | 1 (5%) | 2 (10%) |
| Gait Disturbance | ||
| Grade 1 | 3 (15%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Cognitive Disturbance | ||
| Grade 1 | 2 (10%) | 2 (10%) |
| Grade 2 | 3 (15%) | 1 (5%) |
| Memory Impairment | ||
| Grade 1 | 5 (20%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Alopecia | ||
| Grade 1 | 10 (50%) | 4 (20%) |
| Grade 2 | 3 (15%) | 2 (10%) |
| Adverse Event (AE) . | Acute AE . | Chronic AE . |
|---|---|---|
| . | N = 20 . | N = 20 . |
| Motor Neuropathy | ||
| Grade 1 | – | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Sensory Neuropathy | ||
| Grade 1 | 3 (15%) | 1 (5%) |
| Grade 2 | 2 (10%) | 2 (10%) |
| Radiation Necrosis | ||
| Grade 1 | – | 1 (5%) |
| Xerostomia | ||
| Grade 1 | 4 (20%) | – |
| Nausea | ||
| Grade 1 | 3 (15%) | 3 (15%) |
| Grade 2 | 3 (15%) | – |
| Hearing Loss | ||
| Grade 1 | 1 (5%) | – |
| Grade 2 | – | 1 (5%) |
| Radiation Dermatitis | ||
| Grade 1 | 10 (50%) | – |
| Grade 2 | 1 (5%) | – |
| Fatigue | ||
| Grade 1 | 10 (50%) | 9 (45%) |
| Grade 2 | 3 (15) | 1 (5%) |
| Grade 3 | 1 (5%) | – |
| Headache | ||
| Grade 1 | 4 (20%) | 3 (15%) |
| Grade 2 | 1 (5%) | 2 (10%) |
| Gait Disturbance | ||
| Grade 1 | 3 (15%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Cognitive Disturbance | ||
| Grade 1 | 2 (10%) | 2 (10%) |
| Grade 2 | 3 (15%) | 1 (5%) |
| Memory Impairment | ||
| Grade 1 | 5 (20%) | 2 (10%) |
| Grade 2 | 1 (5%) | 1 (5%) |
| Alopecia | ||
| Grade 1 | 10 (50%) | 4 (20%) |
| Grade 2 | 3 (15%) | 2 (10%) |
1Statistics presented: n (%).
AEs are defined as events experienced within 90 days of the start of RT; otherwise considered chronic maximum toxicities are presented.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
